PROCEPT BioRobotics Sees 9.5x Revenue Surge Since IPO with CEO’s Investor Day Ahead
PROCEPT BioRobotics revenue rose roughly 9.5-fold by fiscal 2025 since its 2021 IPO due to rapid adoption of the AquaBeam robotic BPH system. CEO Larry Wood will host investor day to reveal multi-year revenue and profitability targets and breakeven timing as PROCEPT projects 2026 growth at twice Intuitive Surgical’s rate.
1. Rapid Revenue Growth Since IPO
Since its 2021 IPO, PROCEPT BioRobotics has seen revenue increase roughly 9.5-fold by fiscal 2025, driven by rapid adoption of its AquaBeam automated robotic system for benign prostatic hyperplasia treatment.
2. Leadership Change and Investor Day
Former Edwards Lifesciences executive Larry Wood assumed the CEO role and will host an investor day on February 25, 2026, to unveil multi-year revenue and profitability targets along with the timing of breakeven.
3. Growth Projections and Valuation
PROCEPT remains unprofitable and is valued on an EV/sales basis, but management projects 2026 growth at about twice Intuitive Surgical’s rate and sees optionality in adjacent markets, with breakeven hinging on execution.